Supplementary Methods, Figure 1, Table 1 from A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Methods, Figure 1, Table 1. Supplementary Figure 1: Vascular expression of Dll4 versus CD31 in archive tumor tissue biopsies -Supplementary Table 1: Correlations between VEGFR-2 VQ and Notch1, Notch3, Dll4 Expression in Archive Samples
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361970457